ArticleRSC advances2023
A useful strategy for synthesis of the disaccharide of OSW-1.
Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A flexible, efficient, and practical synthesis route was developed to synthesize an OSW-1 disaccharide. The synthesis took 13 steps from l-arabinose and d-xylose derivatives, and the overall yield was 7.2%. The region preferentially protects various d-xylose hydroxides because the TBS group selectively reacts with this hydroxide at low concentrations due to greater activity at the C-4 hydroxyl of d-xylose. Then, high efficiency selectively protects C-2 hydroxyl and C-3 hydroxyl of d-xylose, respectively. The first high yield of glycosylation on an OSW-1 synthesis disaccharide was achieved by taking sulfide donor 4 with β-PMP anomeric l-arabinose acceptor 12. The cytotoxicity reveals that the analogy has a high IC50 for a variety of cell types. This approach should provide a versatile way to modify OSW-1's disaccharide.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.